PARP1 and ovarian cancer: Recent results have demonstrated that PARP inhibitors could play an emerging role in the maintenance treatment of advanced ovarian cancer with long-term efficacy and improved PFS in patients with newly diagnosed disease experimenting CR or PR to platinum-based chemotherapy (119–121).